Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
P/E ratio for Reneo Pharmaceuticals, Inc. (RPHM)
P/E ratio as of 2023: -0.63
According to Reneo Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.63. At the end of 2022 the company had a P/E ratio of -11.40.
P/E ratio history for Reneo Pharmaceuticals, Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.63 |
| 2022 | -11.40 |
| 2021 | -39.01 |
| 2020 | -18.66 |
| 2019 | -9.39 |
| 2001 | 0.00 |